Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active Against Both Direct and Trans Infection of Primary Cells

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2003 Jan 29

PMID 12552019

Citations 22

Authors

Thomas J Ketas

Ines Frank

Per Johan Klasse

Brian M Sullivan

Jason P Gardner

Catherine Spenlehauer

Mirjana Nesin

William C Olson

John P Moore

Melissa Pope

Affiliations

Soon will be listed here.

Abstract

Inhibitors of human immunodeficiency virus type 1 attachment (CD4-immunoglobulin G subclass 2), CCR5 usage (PRO 140), and fusion (T-20) were tested on diverse primary cell types that represent the major targets both for infection in vivo and for the inhibition of trans infection of target cells by virus bound to dendritic cells. Although minor cell-type-dependent differences in potency were observed, each inhibitor was active on each cell type and trans infection was similarly vulnerable to inhibition at each stage of the fusion cascade.

Citing Articles

Dendritic cells efficiently transmit HIV to T Cells in a tenofovir and raltegravir insensitive manner.

Kim J, Chang E, Sigal A, Baltimore D PLoS One. 2018; 13(1):e0189945.

PMID: 29293546 PMC: 5749731. DOI: 10.1371/journal.pone.0189945.

Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Hutchings C, Koglin M, Olson W, Marshall F Nat Rev Drug Discov. 2017; 16(9):787-810.

PMID: 28706220 DOI: 10.1038/nrd.2017.91.

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection.

Li L, Tian J, Yang K, Zhang P, Jia W Cochrane Database Syst Rev. 2014; (7):CD008439.

PMID: 25063928 PMC: 7173721. DOI: 10.1002/14651858.CD008439.pub3.

Which Antibody Functions are Important for an HIV Vaccine?.

Su B, Moog C Front Immunol. 2014; 5:289.

PMID: 24995008 PMC: 4062070. DOI: 10.3389/fimmu.2014.00289.

HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells.

Rinaldo C Scientifica (Cairo). 2013; 2013:164203.

PMID: 24278768 PMC: 3820354. DOI: 10.1155/2013/164203.

References

Trkola A, Paxton W, Monard S, Hoxie J, Siani M, Thompson D . Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol. 1998; 72(1):396-404. PMC: 109387. DOI: 10.1128/JVI.72.1.396-404.1998. View

Oravecz T, Pall M, Wang J, Roderiquez G, Ditto M, Norcross M . Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans. J Immunol. 1997; 159(9):4587-92. View

Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman R . Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J Virol. 1998; 72(4):2733-7. PMC: 109716. DOI: 10.1128/JVI.72.4.2733-2737.1998. View

Mo H, Monard S, Pollack H, Ip J, Rochford G, Wu L . Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res Hum Retroviruses. 1998; 14(7):607-17. DOI: 10.1089/aid.1998.14.607. View

Chan D, Kim P . HIV entry and its inhibition. Cell. 1998; 93(5):681-4. DOI: 10.1016/s0092-8674(00)81430-0. View

FRANKEL S, Steinman R, Michael N, Kim S, Bhardwaj N, Pope M . Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol. 1998; 72(12):9788-94. PMC: 110490. DOI: 10.1128/JVI.72.12.9788-9794.1998. View

Amzazi S, Ylisastigui L, Bakri Y, Rabehi L, Gattegno L, Parmentier M . The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state. Virology. 1999; 252(1):96-105. DOI: 10.1006/viro.1998.9452. View

Olson W, Rabut G, Nagashima K, Tran D, Anselma D, Monard S . Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol. 1999; 73(5):4145-55. PMC: 104194. DOI: 10.1128/JVI.73.5.4145-4155.1999. View

BERGER E, Murphy P, Farber J . Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999; 17:657-700. DOI: 10.1146/annurev.immunol.17.1.657. View

10.

Hu J, Gardner M, Miller C . Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol. 2000; 74(13):6087-95. PMC: 112107. DOI: 10.1128/jvi.74.13.6087-6095.2000. View

11.

Jacobson J, Lowy I, Fletcher C, ONeill T, Tran D, Ketas T . Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis. 2000; 182(1):326-9. DOI: 10.1086/315698. View

12.

Smith P, Meng G, Sellers M, Rogers T, Shaw G . Biological parameters of HIV-1 infection in primary intestinal lymphocytes and macrophages. J Leukoc Biol. 2000; 68(3):360-5. View

13.

Doms R, Moore J . HIV-1 membrane fusion: targets of opportunity. J Cell Biol. 2000; 151(2):F9-14. PMC: 2192632. DOI: 10.1083/jcb.151.2.f9. View

14.

Shearer W, Israel R, STARR S, Fletcher C, Wara D, Rathore M . Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis. 2000; 182(6):1774-9. DOI: 10.1086/317622. View

15.

Trkola A, Ketas T, Nagashima K, Zhao L, Cilliers T, Morris L . Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol. 2001; 75(2):579-88. PMC: 113953. DOI: 10.1128/JVI.75.2.579-588.2001. View

16.

Spenlehauer C, KIRN A, Aubertin A, Moog C . Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. J Virol. 2001; 75(5):2235-45. PMC: 114807. DOI: 10.1128/JVI.75.5.2235-2245.2001. View

17.

Nagashima K, Thompson D, Rosenfield S, Maddon P, Dragic T, Olson W . Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis. 2001; 183(7):1121-5. DOI: 10.1086/319284. View

18.

LaBranche C, Galasso G, Moore J, Bolognesi D, Hirsch M, Hammer S . HIV fusion and its inhibition. Antiviral Res. 2001; 50(2):95-115. DOI: 10.1016/s0166-3542(01)00130-9. View

19.

Wesselingh S, Thompson K . Immunopathogenesis of HIV-associated dementia. Curr Opin Neurol. 2001; 14(3):375-9. DOI: 10.1097/00019052-200106000-00018. View

20.

Johnson D, Huber M . Directed egress of animal viruses promotes cell-to-cell spread. J Virol. 2001; 76(1):1-8. PMC: 135733. DOI: 10.1128/jvi.76.1.1-8.2002. View